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ASSESSING THE EFFECT OF STATINS IN LOWERING THE RISK OF 
STROKE AND PREVENTING CEREBRAL ISCHEMIA IN PATIENTS WITH 
HYPERCHOLESTEROLEMIA 
BY WAFA ALSULAIMAN 
ABSTRACT 
 Numerous analyses have explored the role of statins in reducing stroke incidence, 
reducing cerebral ischemia in hypercholesterolemic patients, and preventing ischemic 
stroke. This paper aims to assess the effect of statins in lowering the risk of stroke and 
preventing cerebral ischemia in patients with hypercholesterolemia. To achieve this 
objective, the literature was reviewed, randomized control tests were analyzed, and a 
systematic review was performed. 
The risk of developing cerebral ischemia was found to be reduced in 
hypercholesterolemic patients and patients with a history of cerebrovascular disease. 
However, it is unknown whether this reduction in incidence is a result of the drug, which 
reduces low-density lipoprotein levels in the blood, or to statins’ pleotropic effects on the 
vascular endothelium. 
Since their discovery, statins have proven to be beneficial in controlling 
cholesterol blood levels. Moreover, statins have been shown to have pleotropic effects  
after a certain period of use, one of which is lowering ischemic stroke incidence in 
hypercholesterolemic patients. Most recently, statins have been found to lower systolic 
blood pressure. It is not yet clear whether it has a significant effect on mortality or 
whether or not it is linked to statins. 
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INTRODUCTION 
Cholesterol 
The cholesterol molecule was discovered almost 300 years ago in the 1780s. 
Because of its unique property of being insoluble in water, it can be either helpful, such 
as in membrane composition, or deadly, such as when it is deposited within the vascular 
endothelium. The general idea of cholesterol transport involves esterification and the 
packing of the resultant esters in the lipoprotein molecule (1). 
Cholesterol Structure and Function 
Cholesterol is a complex four-ring structure achieved through the action of 30 
enzymes (1) (Figure 1); its substrate is a two-carbon acetate. Cholesterol is responsible 
for cell membrane integrity, an energy source, and a precursor of essential hormones, 
including steroid hormones, vitamin D, and bile salts. Lipoproteins facilitate the transport 
of cholesterol to the peripheral tissue, with many types; each type has a specific function 
(Table 1). In general, cholesterol’s principle function is to be present in the membrane’s 
phospholipid bilayer between polar head groups, thereby reducing membrane fluidity. 
The amount of cholesterol required to maintain its function is low (2). 
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Figure 1. Cholesterol’s four-ring biochemical structure. 
 
Sources of cholesterol and Its Biosynthesis 
Cholesterol is generally derived from the diet or synthesized endogenously. 
Endogenous biosynthesis sites include the liver and the central nervous system (CNS) 
(Figure 2) (1). Cholesterol is a lipoprotein, and lipoproteins are divided into 
chylomicrons, high-density lipoproteins, low-density lipoproteins, and very low-density 
lipoproteins. Past research has established that elevated very low-density lipoproteins 
(VLDL) levels and low-density lipoprotein (LDL) levels are major risk factors for 
atherosclerosis (6). 
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Table 1. Apolipoprotein types and functions (7). 
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Figure 2. Key steps in cholesterol biosynthesis. This figure illustrates the presumed 
function of the compounds involved in cholesterol biosynthesis, starting by the rate 
limiting step controlled by 3-Hydroxy-3-MethylGlutaryl-CoenzymeA, to the final 
product, cholesterol. Abbreviations: PP, pyrophosphate; SMC, smooth muscle cell; and 
CoQ, coenzyme Q (2). 
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Figure 3. Lipoprotein metabolism. Abbreviations: apoB48, apolipoprotein B48; apo A1, 
apolipoprotein A1; apoB100, apolipoprotein B100; TG, Triglyceride; LRP, LDL 
receptor-like protein; ABCA1, ATP-binding cassette A1; SRA1, SRB1, CD36, 3 
members of the scavenger receptor family; CETP, cholesteryl ester transfer protein; 
VLDL, very low-density lipoprotein; IDL, intermediate density lipoprotein; LDL, low-
density lipoprotein; and HDL, high-density lipoprotein (2). 
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Metabolism 
The thoracic lymph duct is chylomicrons’ main passageway into the blood 
circulation. Chylomicrons are composed mainly of triglyceride, the main component of a 
normal fat diet, and formed by the re-synthesis of triglyceride and a reaction involving 
combining triglyceride after re-synthesis with Apo B48. The core of chylomicrons is 
formed by free cholesterol absorbed from the gut (2). Chylomicrons enter the intestine 
with the help of enterocytes. In the blood circulation, lipoprotein lipase, which functions 
as a hydrolyzing enzyme, is situated at the endothelial surface of vascular organ tissue—
for example, skeletal muscles. Upon the entrance of chylomicrons into the blood 
circulation, the lipoprotein lipase enzyme initiates the hydrolysis of triglyceride, which in 
turn results in the release of fatty acids, monoglyceride, and a smaller chylomicron 
particle. The released chylomicrons components are taken up by the liver, fat tissues, and 
myocytes (1). Cholesterol is also exported by the liver in the form VLDL, which, in a 
process similar to chylomicron formation, combines triglyceride with Apo B100. 
Cholesterol is the main component for the formation of bile salts. Bile salts are 
formed in the liver and have a detergent property, including fat emulsification. They are 
mainly divided into primary and secondary bile salt acids, where the primary bile salt 
acids are cholic acid and chenodeoxycholic acid, and the secondary bile salt acids are 
deoxycholic acid and lithocholic acid. This was first described in detail by Gibbons in 
1982. Primary and secondary bile salt acids are recycled by absorption through the 
terminal ileum, removed from circulation by the liver, and then re-secreted into the 
intestine through bile (2). 
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Intestinal Absorption 
Cholesterol esterase, an important enzymes involved in intestinal cholesterol 
absorption, converts cholesterol ester into unesterified cholesterol. This then enters 
intestinal mixed micelles, which by this time contain dietary cholesterol, plant sterols, 
and bile. After, the mixed micelles carry cholesterol and cholesterol components pass into 
enterocytes in the intestine through Niemann-Pick C1-Like 1 (NPC1L1) channel (Figure 
4) (1). Only cholesterol not containing plant sterol enters back into the body’s circulation; 
this is achieved by the function of ATP-binding cassette G5/G8 (1). 
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Figure 4. Intestinal cholesterol absorption. This figure shows that Niemann-Pick C1-Like 
1 (NCP1L1) channel absorbs sterols, while plant sterols are not absorbed and carried 
back to the gut through ATP-binding cassette G5/G8 channel. Acetyl-CoA does 
cholesterol esterification: the resultant cholesterol acyl transferase is transferred to the 
endoplasmic reticulum and Golgi apparatus, where it undergoes series of reactions 
resulting in a complex called chylomicrons composed of, lipids, cholesterol acyl 
transferase and apolipoprotein B48. Free cholesterol is carried through ATP-binding 
cassette A1 to leave the gut lumen and combine with nascent HDL at the capillary site. 
Abbreviations: TG, triglyceride; MTP, microsomal triglyceride Transfer protein; and 
RBC, red blood cell (2). 
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Hypercholesterolemia 
Hypercholesterolemia, indicated by high blood cholesterol levels (> 240 mg/dL), 
is a common condition affecting 34 million American adults. According to the Center for 
Disease Control and Prevention, a screening conducted between 2006 and 2011 revealed 
a high prevalence of high cholesterol across the United States, with the highest 
prevalence in the east coast (Figure 5) (3). 
 
 
Figure 5. Prevalence of hypercholesterolemia in the United States. 
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Inherited forms of the condition include heterozygous familial 
hypercholesterolemia, homozygous familial hypercholesterolemia, and primary moderate 
hypercholesterolemia (3). 
 
Heterozygous familial hypercholesterolemia is an autosomal dominant condition 
associated with a higher incidence of early coronary disease (5). It is caused by LDL 
receptor deficiency and results when one parental gene encoding for the LDL receptor is 
non-functional (3). Homozygous familial hypercholesterolemia is characterized by a 
complete non-functional gene encoding for the LDL receptor, “receptor negative” or 
“receptor defective,” indicating an extremely low-functioning LDL receptor. Primary 
moderate hypercholesterolemia is characterized by serum LDL cholesterol levels 
(>160mg/dL) without apparent genetic defect in the gene encoding for the LDL receptor 
(5). 
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Stroke 
A stroke is defined as a change in the amount of blood flow to the brain: an 
increase in blood results in a hemorrhagic stroke, and a decrease in blood results in an 
ischemic stroke. This can cause many clinical outcomes depending on the extent of the 
decrease or increase in blood flow, i.e., the extent of ischemia or hemorrhage (4). 
According to the Clinical Practice Guidelines for the Management of Stroke 
Patients in Primary Health Care, strokes can be divided into types and subtypes according 
to certain factors, including the lesion’s site, size, onset, and morphology. Combined with 
certain parameters that are specific to each patient, a specific clinical outcome arises. 
This clinical classification is described in Figure 10. 
 
The anatomical orientation of the cerebral vascular structure is very distinct from 
the rest of the body, in that microvascular system cells are extremely connected, 
demonstrating a one-unit structure. The cerebral microvascular structure shown in Figure 
5 demonstrates how the astrocyte end-feet’s relationship with the endothelial lining is 
altered during ischemia (Figure 6) (4). This relationship explains the fast transmission of 
inflammatory response resulting from ischemia and immunologic response starting by 
chemoattractants and IL release, causing the vasculature to change and disrupting the 
normal anatomical relationship (4). 
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Figure 6. Clinical classification of stroke (4). 
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Normal cerebral microvasculature 
The cerebral microvascular structure shown in Figure 7 shows the normal 
astrocyte end-feet’s relationship with the endothelial lining, with the astrocytes encircling 
the vessel. This explains why the cerebral vascular structure is highly selective and highly 
connected, demonstrating a web-like connection (4). 
 
Figure 7. Normal cerebral microvascular structure. This figure illustrates the anatomical 
components of the cerebral vessel, these components are, basal lamina, endothelial cells 
and astrocytes, it also shows the astrocyte end-feet relationship forming a boundary 
around the cerebral vessel (4). 
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Cerebral vascular events in ischemia 
The event of cerebral ischemia, i.e., a decrease in blood flow, initiates endothelial 
injury, which results in increased capillary permeability. This event causes a series of 
reactions, beginning with capillary inflammation and immunological response, and 
ending with disrupted contact between the astrocyte end-feet and the cell (4). 
 
 
Figure 8. Effects of ischemia on microvascular integrity. (A) Shows the normal 
anatomical features of the cerebral vessel, intact astrocyte end-feet circumferential 
boundary with cerebral vessel. (B) Shows the sign of ischemia, which is increased 
permeability. (C) Shows increased permeability due to leukocyte adhesion. (D) Shows 
the end result of ischemia of the cerebral vessels, loss of astrocyte end-feet 
circumferential boundary with cerebral vessel, disrupted basal lamina, high permeability 
(D) (4). 
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Statins 
Lipid accumulation in the body has been proven harmful, as it affects the 
prevalence of mortality and morbidity (6). That said, scientists concluded that this issue 
must be met. Over years of experimentation, many types of lipid-lowering agents were 
discovered. Most types have many reported side-effects and have not yet achieved the 
desired effects on lipid levels in the blood. 
Microbiologist Akira Endo first discovered statins in the 1970s, through her 
discovery of a fungal metabolite that prevents the function of the rate-limiting enzyme of 
cholesterol synthesis, HMG-CoA reductase of Penicillium citrinum; this product was 
named compactin. In the late 1970s, another inhibitor was discovered that was 
compatible for the use in humans with good inhibition of HMG-CoA reductase; this 
product was named lovastatin (6). 
 
Mechanism of Action 
Statins inhibit hepatic HMG-CoA reductase, which results in lower LDL levels—
hence, the therapeutic use of this family of drugs in hypercholesterolemia (Figure 8) (6). 
The effect of statins is determined by multiple aspects, including the degree of intestinal 
absorption, hepatic uptake, and elimination, which is determined by whether the statin 
has a hydrophilic or lipophilic structure (Table 2) (2). 
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Adverse Effects 
Statins’ adverse effects include liver toxicity, which has not been reported among 
more than 1%; increased risk of diabetes following treatment (20%-30%); and myopathy 
and myalgia, which have been commonly reported in the medical practice, though the 
exact cause and pathology remains unclear (6). 
 
 Table 2. Features of clinically used statins (2). 
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Figure. 9. Synthetic structure of major statins. Compactin is not for therapeutic use. 
Closed-ring are lovastatin and simvastatin. Synthetically synthesized are fluvastatin, 
atorvastatin, rosuvastatin, and pitavastatin (6). 
 
 
 
 
Hypercholesterolemia as a Risk Factor for Stroke 
Stroke is a common disease worldwide. Its occurrence depends on multiple risk 
factors, two of which are high blood cholesterol and LDL levels. Many clinical trials 
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seeking to understand the adverse effects of statins and other drugs that have been 
manufactured to control blood cholesterol levels have found that lower cholesterol levels 
decrease the incidence of cerebrovascular ischemia (28). Statins are defined as a family 
of drugs that control and inhibit cholesterol production by binding to 3-hydroxymethyl-3-
glutaryl coenzyme A (HMG-CoA) reductase. The end result is a lower LDL level in the 
blood, which in turn benefits the outcome of many disease states, including 
cardiovascular disease and stroke (27). 
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Aims 
A high LDL blood plasma level is associated with increased risk of heart disease 
and cerebrovascular events. Increased LDL blood plasma levels could be a result of 
familial hypercholesterolemia, systemic disease, or a high-cholesterol diet. This condition 
is one of the most important risk factors for cerebrovascular events, and most 
importantly, ischemic stroke. Before the launch of lipid-lowering drugs, the incidence of 
stroke due to uncontrolled high cholesterol levels was high. After the start of statin use, 
research found a strong association between statin therapy as a first-line treatment for 
hypercholesterolemia and a lower incidence of stroke, reduced neurologic deficit 
afterwards, lower death rate, and possible primary prevention of ischemic stroke. This 
study aims to achieve the following objective: 
 
• To determine if statins’ lipid-lowering agents can be administered as a preventive 
therapy for stroke in patients diagnosed with hypercholesterolemia in order to 
prevent ischemic stroke. 
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PUBLISHED STUDIES 
 
Role of Statins in Ischemic and Hemorrhagic Stroke 
Statins have multiple organ effects; they affect the liver, the musculoskeletal 
system, and the nervous system. Controlled clinical trials with randomized blinded 
assignment of patients to treatment groups for statin or placebo treatment were conducted 
to obtain valid data about statins’ adverse effects (29). The Stroke Prevention by 
Aggressive Reduction in Cholesterol Levels (SPARCL) investigators conducted a study 
that allocated patients with a history of transient ischemic attack or thrombotic stroke into 
two groups: one group was treated with statins, and the other group with a placebo. This 
study found that treatment with statins allows for significant protection against strokes 
due to vascular damage, i.e., thrombotic stroke (30). 
 New evidence has revealed that treatment with a statin prior to the occurrence of 
severe ischemic stroke is effective in generating a better neurologic presentation and a 
lower death rate. However, a non-favorable effect of statins is an increased incidence of 
brain hemorrhage (38). 
Every patient death has a primary cause, so it can be difficult to attribute death to 
stroke, rather than other risk factors. Fatal and non-fatal strokes could not be easily 
identified, as the major trials involved in this differentiation were not examined in this 
review. From the drug trials examined in this study (19), eight had zero fatalities, and 
they were not given much emphasis in the analysis of data obtained. Hemorrhagic stroke 
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association was observed in 12 trials. The procedure included 49,843 randomized patients 
(19). 
Statins and Ischemic Stroke Prevention 
Although statins were not primarily designed to protect against ischemic stroke, 
randomized studies have generated significant evidence indicating that statins lower the 
incidence of cerebrovascular events. For example, clinical trials and meta-analysis studies 
aiming to explore the prevention of coronary heart disease using simvastatin and 
pravastatin revealed that these drugs significantly reduced ischemic stroke in coronary 
heart disease (CHD) patients (32%); result of that significance is what caused the Food 
and Drug Administration to approve the use of pravastatin and simvastatin for clinical 
use in preventing stroke (32, 33). 
A randomized clinical trial with a large sample size comprising patients suffering 
from previous cerebrovascular ischemia included a subgroup analysis of the effect of 
statin treatments on the reoccurrence of ischemic stroke. This analysis showed a 
significant benefit in lowering the recurrence of ischemic stroke in these patients (Table 
1) (28). To further establish and confirm the strong evident relationship between statin-
treated high-serum LDL and a lower incidence of ischemic stroke, a meta-analysis and a 
systemic review of the available data pertaining to the frequency of occurrence of 
ischemic stroke and transient ischemic attacks through the year 2015 were analyzed. This 
analysis included 3,374 individuals diagnosed with heterozygous familial 
hypercholesterolemia. The control group was the general population in the same area, and 
the data analyzed in the period of time before the year 1987 i.e. before statin 
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administration to patients with heterozygous familial hypercholesterolemia and after the 
year 1987 when lovastatin was released. The analysis concluded that patients treated with 
statins had lower chance of ischemic stroke incidence, with an odds ratio of 0.251 and 
p<0.01, compared to a higher risk of stroke incidence for patients not treated with statins, 
with an odds ratio of 7.658 and p<0.01. These results indicate that after statins were used, 
the risk of cerebrovascular events was reduced in patients with heterozygous familial 
hypercholesterolemia. This further confirms the beneficial relationship between statin use 
and lower stroke incidence (31). Moreover, according to a study conducted to assess how 
statins affect patients with a high risk of stroke and coronary events, researchers 
concluded that the administration of simvastatin substantially reduced the risk of stroke in 
patients with multiple risk factors with evidence of protective revascularization (20). 
Other therapeutic lipid-lowering drugs, such as fibrates, omega-3 fatty acids, and 
bile acid sequestrants (resins), are available for use for patients with high blood LDL 
levels, but their effect on improving cerebrovascular events has not yet been proven. 
Statins remain the first line of therapy for patients with high blood LDL levels (40). 
Statin’s pleotropic effects 
A study investigating the effect of statins on the endothelium concluded that 
statins in fact protect the vessel wall’s endothelial lining; this effect is one of statin’s 
benefits, i.e., pleotropic effects (Figure 10). This is separate from its main function: 
lowering LDL levels. The odds ratio for stroke incidence was found to be significantly 
reduced as well (18). 
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Figure 10. Pleotropic effects of statins. When the subendothelial space is injured, LDL 
enters and acts along with monocyte chemotactic protein-1 as an attractant for monocyte 
accumulation in the subendothelial space, monocyte then is converted to macrophage. 
Moreover after LDL undergoes oxidation, foam cells remove it. The formation of fatty 
streaks predispose to atherosclerosis. Statin also affect coagulation mechanism, i.e. 
development of inflammation within the plaque, plaque thrombogenic complications 
(42). 
 
 
 
 
Before and After the Statins Era 
Based on numerous clinical trials, randomized double-blind clinical trials, meta-
analyses of epidemiological data, and subgroup analyses of data pertaining to patients 
suffering from hypercholesterolemia, it is evident that before the era of statin use, 
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patients with high blood LDL levels had a high risk of incidence of cerebrovascular 
events and a higher death rate. A meta-analysis of patient data after the generalization of 
statin therapy to patients with high blood LDL levels showed the therapy’s clear benefits, 
including a lower risk of cerebrovascular events, decreased neurological deficit at the 
presentation of stroke, and lower mortality when statin therapy is administered prior to 
ischemic brain events. 
With regard to the precise effects of statins on the development of stroke or the 
conditions that cause it, the duration and regimen brings about the difference. This can be 
attributed to the dosage, the chemical structure, and the main reason that prompted the 
administration of the drug (21). 
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Table 3. Trials of statin administration and primary prevention among patients with 
cardiovascular disease (28). 
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DISCUSSION 
In a number of regions, studies on statins have shown their therapeutic effects, 
adverse effects, contraindications, drug interactions, and associations with other health 
conditions (21). Some effects are desirable, whereas others are not. Generally, statins 
have been found to reduce the incidence of all strokes without causing hemorrhage or 
hemostasis in the brain (20). In cases of hypertension, hypercholesterolemia, diabetes, 
previous stroke, and coronary heart disease, the incidence of stroke is significantly 
reduced after the administration of statins (20). This can be attributed to the vascular 
events that follow the administration of these drugs (20, 22). 
With regard to brain hemorrhage, a study examining statins’ effect on stroke 
outcome found no increase in hemorrhagic stroke due to statin drugs. Moreover, the 
study showed a positive association between high cholesterol levels and hemorrhagic 
stroke incidence, though these results contradict multiple clinical trials conducted to 
study this association (23). 
Statins can also reduce blood pressure up to 5mmHg, and this directly reduces the 
incidence of stroke by approximately 27%. However, other studies have shown that there 
is no change in diastolic and systolic pressure between the beginning and end of a statin 
drug trial (24), which likely suggests that the change is only in the peripheral parts of the 
cardiovascular system (25). This finding prompts more research on hypertension disease 
to evaluate the trend in reducing stroke incidence. 
Statins also generate anti-inflammatory effects by binding to important biological 
markers and inhibiting the function of chemoattractants that induce inflammation. This 
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therefore inhibits the instability of plaque and the development of atherosclerosis (26). 
Furthermore, statins reduce media and intima thickness. They also reduce the presence of 
LDL cholesterol in the surface of blood vessels, thereby leaving no room for other 
materials to attach, which can lead to a reduction in lumen size (18). Statins have 
pleiotropic effects, but their main effect is reducing LDL levels 
CONCLUSION 
Stroke is a common cause of death, and there are many types of stroke: ischemic, 
hemorrhagic, thrombotic, and strokes that are caused by ruptured aneurysms. Age 
typically affects a human being’s general health, and accordingly, most elderly 
individuals suffer from chronic diseases that worsen their odds of suffering from stroke, 
diabetes, hypertension, and hypercholesterolemia. This paper, which conducted a 
literature review and investigated hypercholesterolemia and its relation to stroke, 
specifically ischemic stroke, concluded that statins affect multiple aspects of the human 
vascular physiology, including the chemistry of lipid metabolism and lowering 
mechanisms. Statin drugs effectively lower LDL levels and thin the vessel walls, thus 
preventing plaque from attaching, and thereby preventing stroke (thrombosis). 
Despite statin therapy’s favorable effect on ischemic stroke, there is controversy 
about whether it has a negative or lethal impact on patients with a history of intracerebral 
hemorrhage. In clinical practice, there is reasonable concern that statins should not be 
used as a treatment in cases of newly occurring intracerebral hemorrhage, hospitalization, 
or individuals at high risk for ICH. Therefore, the decision to use statin therapy should 
take into consideration the patient’s cardiovascular history. 
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Now that the positive effects of statin therapy for effectively preventing ischemic 
stroke and lowering LDL levels have been established, the next provisional step in this 
area involves studying what duration and dose most effectively bring about these effects. 
Moreover, future research could explore how to better prevent disease by studying and 
investigating the effects of the drug’s chemistry on other aspects of the cerebrovascular 
system. 
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